Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
Identifieur interne : 001284 ( PubMed/Corpus ); précédent : 001283; suivant : 001285Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
Auteurs : Parul U. Gandhi ; Sheryl L. Chow ; Thomas S. Rector ; Henry Krum ; Hanna K. Gaggin ; John J. Mcmurray ; Michael R. Zile ; Michel Komajda ; Robert S. Mckelvie ; Peter E. Carson ; James L. Januzzi ; Inder S. AnandSource :
- Journal of cardiac failure [ 1532-8414 ] ; 2017.
English descriptors
- KwdEn :
- Aged, Angiotensin II Type 1 Receptor Blockers (therapeutic use), Biphenyl Compounds (therapeutic use), Cause of Death (trends), Female, Follow-Up Studies, Heart Failure (blood), Heart Failure (drug therapy), Heart Failure (mortality), Hospitalization (statistics & numerical data), Humans, Insulin-Like Growth Factor Binding Proteins (blood), Male, Prognosis, Risk Factors, Stroke Volume (physiology), Survival Rate (trends), Tetrazoles (therapeutic use), Time Factors, United States (epidemiology).
- MESH :
- chemical , blood : Insulin-Like Growth Factor Binding Proteins.
- chemical , therapeutic use : Angiotensin II Type 1 Receptor Blockers, Biphenyl Compounds, Tetrazoles.
- blood : Heart Failure.
- drug therapy : Heart Failure.
- epidemiology : United States.
- mortality : Heart Failure.
- physiology : Stroke Volume.
- statistics & numerical data : Hospitalization.
- trends : Cause of Death, Survival Rate.
- Aged, Female, Follow-Up Studies, Humans, Male, Prognosis, Risk Factors, Time Factors.
Abstract
The prognostic merit of insulin-like growth factor-binding protein 7 (IGFBP7) is unknown in heart failure and preserved ejection fraction (HFpEF).
DOI: 10.1016/j.cardfail.2016.06.006
PubMed: 27317843
Links to Exploration step
pubmed:27317843Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.</title><author><name sortKey="Gandhi, Parul U" sort="Gandhi, Parul U" uniqKey="Gandhi P" first="Parul U" last="Gandhi">Parul U. Gandhi</name><affiliation><nlm:affiliation>Section of Cardiovascular Medicine, VA Connecticut, West Haven, Connecticut; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Chow, Sheryl L" sort="Chow, Sheryl L" uniqKey="Chow S" first="Sheryl L" last="Chow">Sheryl L. Chow</name><affiliation><nlm:affiliation>Western University of Health Sciences, Pomona, California.</nlm:affiliation></affiliation></author><author><name sortKey="Rector, Thomas S" sort="Rector, Thomas S" uniqKey="Rector T" first="Thomas S" last="Rector">Thomas S. Rector</name><affiliation><nlm:affiliation>Veterans Affairs Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation><nlm:affiliation>CCRE Therapeutics, Monash University, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gaggin, Hanna K" sort="Gaggin, Hanna K" uniqKey="Gaggin H" first="Hanna K" last="Gaggin">Hanna K. Gaggin</name><affiliation><nlm:affiliation>Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Mcmurray, John J" sort="Mcmurray, John J" uniqKey="Mcmurray J" first="John J" last="Mcmurray">John J. Mcmurray</name><affiliation><nlm:affiliation>British Heart Foundation Glasgow Cardiovascular Research Center, Glasgow, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Zile, Michael R" sort="Zile, Michael R" uniqKey="Zile M" first="Michael R" last="Zile">Michael R. Zile</name><affiliation><nlm:affiliation>RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina.</nlm:affiliation></affiliation></author><author><name sortKey="Komajda, Michel" sort="Komajda, Michel" uniqKey="Komajda M" first="Michel" last="Komajda">Michel Komajda</name><affiliation><nlm:affiliation>Université Paris 6; Pitie Salpetriere Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mckelvie, Robert S" sort="Mckelvie, Robert S" uniqKey="Mckelvie R" first="Robert S" last="Mckelvie">Robert S. Mckelvie</name><affiliation><nlm:affiliation>Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Carson, Peter E" sort="Carson, Peter E" uniqKey="Carson P" first="Peter E" last="Carson">Peter E. Carson</name><affiliation><nlm:affiliation>Washington VAMC and Georgetown University, Washington, DC.</nlm:affiliation></affiliation></author><author><name sortKey="Januzzi, James L" sort="Januzzi, James L" uniqKey="Januzzi J" first="James L" last="Januzzi">James L. Januzzi</name><affiliation><nlm:affiliation>Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org.</nlm:affiliation></affiliation></author><author><name sortKey="Anand, Inder S" sort="Anand, Inder S" uniqKey="Anand I" first="Inder S" last="Anand">Inder S. Anand</name><affiliation><nlm:affiliation>Veterans Affairs Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27317843</idno><idno type="pmid">27317843</idno><idno type="doi">10.1016/j.cardfail.2016.06.006</idno><idno type="wicri:Area/PubMed/Corpus">001284</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001284</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.</title><author><name sortKey="Gandhi, Parul U" sort="Gandhi, Parul U" uniqKey="Gandhi P" first="Parul U" last="Gandhi">Parul U. Gandhi</name><affiliation><nlm:affiliation>Section of Cardiovascular Medicine, VA Connecticut, West Haven, Connecticut; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.</nlm:affiliation></affiliation></author><author><name sortKey="Chow, Sheryl L" sort="Chow, Sheryl L" uniqKey="Chow S" first="Sheryl L" last="Chow">Sheryl L. Chow</name><affiliation><nlm:affiliation>Western University of Health Sciences, Pomona, California.</nlm:affiliation></affiliation></author><author><name sortKey="Rector, Thomas S" sort="Rector, Thomas S" uniqKey="Rector T" first="Thomas S" last="Rector">Thomas S. Rector</name><affiliation><nlm:affiliation>Veterans Affairs Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation><nlm:affiliation>CCRE Therapeutics, Monash University, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gaggin, Hanna K" sort="Gaggin, Hanna K" uniqKey="Gaggin H" first="Hanna K" last="Gaggin">Hanna K. Gaggin</name><affiliation><nlm:affiliation>Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation></affiliation></author><author><name sortKey="Mcmurray, John J" sort="Mcmurray, John J" uniqKey="Mcmurray J" first="John J" last="Mcmurray">John J. Mcmurray</name><affiliation><nlm:affiliation>British Heart Foundation Glasgow Cardiovascular Research Center, Glasgow, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Zile, Michael R" sort="Zile, Michael R" uniqKey="Zile M" first="Michael R" last="Zile">Michael R. Zile</name><affiliation><nlm:affiliation>RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina.</nlm:affiliation></affiliation></author><author><name sortKey="Komajda, Michel" sort="Komajda, Michel" uniqKey="Komajda M" first="Michel" last="Komajda">Michel Komajda</name><affiliation><nlm:affiliation>Université Paris 6; Pitie Salpetriere Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mckelvie, Robert S" sort="Mckelvie, Robert S" uniqKey="Mckelvie R" first="Robert S" last="Mckelvie">Robert S. Mckelvie</name><affiliation><nlm:affiliation>Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Carson, Peter E" sort="Carson, Peter E" uniqKey="Carson P" first="Peter E" last="Carson">Peter E. Carson</name><affiliation><nlm:affiliation>Washington VAMC and Georgetown University, Washington, DC.</nlm:affiliation></affiliation></author><author><name sortKey="Januzzi, James L" sort="Januzzi, James L" uniqKey="Januzzi J" first="James L" last="Januzzi">James L. Januzzi</name><affiliation><nlm:affiliation>Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org.</nlm:affiliation></affiliation></author><author><name sortKey="Anand, Inder S" sort="Anand, Inder S" uniqKey="Anand I" first="Inder S" last="Anand">Inder S. Anand</name><affiliation><nlm:affiliation>Veterans Affairs Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of cardiac failure</title><idno type="eISSN">1532-8414</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Angiotensin II Type 1 Receptor Blockers (therapeutic use)</term><term>Biphenyl Compounds (therapeutic use)</term><term>Cause of Death (trends)</term><term>Female</term><term>Follow-Up Studies</term><term>Heart Failure (blood)</term><term>Heart Failure (drug therapy)</term><term>Heart Failure (mortality)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans</term><term>Insulin-Like Growth Factor Binding Proteins (blood)</term><term>Male</term><term>Prognosis</term><term>Risk Factors</term><term>Stroke Volume (physiology)</term><term>Survival Rate (trends)</term><term>Tetrazoles (therapeutic use)</term><term>Time Factors</term><term>United States (epidemiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Insulin-Like Growth Factor Binding Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin II Type 1 Receptor Blockers</term><term>Biphenyl Compounds</term><term>Tetrazoles</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Heart Failure</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Stroke Volume</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Cause of Death</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Prognosis</term><term>Risk Factors</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The prognostic merit of insulin-like growth factor-binding protein 7 (IGFBP7) is unknown in heart failure and preserved ejection fraction (HFpEF).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27317843</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>10</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8414</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of cardiac failure</Title><ISOAbbreviation>J. Card. Fail.</ISOAbbreviation></Journal><ArticleTitle>Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.</ArticleTitle><Pagination><MedlinePgn>20-28</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1071-9164(16)30109-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cardfail.2016.06.006</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The prognostic merit of insulin-like growth factor-binding protein 7 (IGFBP7) is unknown in heart failure and preserved ejection fraction (HFpEF).</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Baseline IGFBP7 (BL-IGFBP7; n = 302) and 6-month change (Δ; n = 293) were evaluated in the Irbesartan in Heart Failure and Preserved Ejection Fraction (I-PRESERVE) trial. Primary outcome was all-cause mortality or cardiovascular hospitalization with median follow-up of 3.6 years; secondary outcomes included HF events. Median BL-IGFBP7 concentration was 218 ng/mL. BL-IGFBP7 was significantly correlated with age (R(2) = 0.13; P < .0001), amino-terminal pro-B-type NP (R(2) = 0.22; P < .0001), and estimated glomerular filtration rate (eGFR; R(2) = 0.14; P < .0001), but not with signs/symptoms of HFpEF. BL-IGFBP7 was significantly associated with the primary outcome (hazard ratio [HR] = 1.007 per ng/mL; P < .001), all-cause mortality (HR = 1.008 per ng/mL; P < .001), and HF events (HR = 1.007 per ng/mL; P < .001). IGFBP7 remained significant for each outcome after adjustment for ln amino-terminal pro-B-type NP and eGFR but not all variables in the I-PRESERVE prediction model. After 6 months, IGFBP7 did not change significantly in either treatment group. ΔIGFBP7 was significantly associated with decrease in eGFR in patients randomized to irbesartan (R(2) = 0.09; P = .002). ΔIGFBP7 was not independently associated with outcome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Higher concentrations of IGFBP7 were associated with increased risk of cardiovascular events, but after multivariable adjustment this association was no longer present. Further studies of IGFBP7 are needed to elucidate its mechanism.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">www.clinicaltrials.gov, NCT00095238.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Parul U</ForeName><Initials>PU</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, VA Connecticut, West Haven, Connecticut; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Sheryl L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Western University of Health Sciences, Pomona, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rector</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Veterans Affairs Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krum</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CCRE Therapeutics, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaggin</LastName><ForeName>Hanna K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMurray</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>British Heart Foundation Glasgow Cardiovascular Research Center, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zile</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komajda</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Université Paris 6; Pitie Salpetriere Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKelvie</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Peter E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Washington VAMC and Georgetown University, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Januzzi</LastName><ForeName>James L</ForeName><Initials>JL</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Inder S</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Veterans Affairs Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00095238</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Fail</MedlineTA><NlmUniqueID>9442138</NlmUniqueID><ISSNLinking>1071-9164</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018969">Insulin-Like Growth Factor Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102529">insulin-like growth factor binding protein-related protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>J0E2756Z7N</RegistryNumber><NameOfSubstance UI="C081309">irbesartan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047228" MajorTopicYN="N">Angiotensin II Type 1 Receptor Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018969" MajorTopicYN="N">Insulin-Like Growth Factor Binding Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">insulin-like growth factor-binding protein 7</Keyword><Keyword MajorTopicYN="N">preserved left ventricular function</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>02</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27317843</ArticleId><ArticleId IdType="pii">S1071-9164(16)30109-9</ArticleId><ArticleId IdType="doi">10.1016/j.cardfail.2016.06.006</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001284 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001284 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27317843
|texte= Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27317843" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |